Prokidney

Prokidney Stock-Based Compensation

The Stock-Based Compensation (SBC) of Prokidney (PROK) as of Nov 15, 2026 is 25.34 M USD. In the previous year, Stock-Based Compensation (SBC) was 29.37 M USD — a change of -13.74% (lower).

Stock-Based Compensation

25.34 MUSD

YoY

-13.74%

Last updated:

Stock-Based Compensation (SBC) of Prokidney is 2025 25.34 M USD. Stock-Based Compensation (SBC) of Prokidney was 2024 29.37 M USD. It decreases by -13.74% lower compared to the previous year.

The Prokidney Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
498.00 USD
Jan 1, 2020
730,000.00 USD
Jan 1, 2021
699,000.00 USD
Jan 1, 2022
74.47 M USD
Jan 1, 2023
30.85 M USD
Jan 1, 2024
29.37 M USD
Jan 1, 2025
25.34 M USD
The Prokidney Stock-Based Compensation history
YEARStock-Based CompensationYoY
25.34 MUSD-13.74%
29.37 MUSD-4.78%
30.85 MUSD-58.58%
74.47 MUSD+10,553.65%
699,000.00USD-4.25%
730,000.00USD+146,486.35%
498.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prokidney Stock analysis

What does Prokidney do? Prokidney Corp, based in Winston-Salem, North Carolina, is a clinical-stage biotechnology company focused on developing cell therapy platforms for chronic kidney diseases. The company employs 231 people and is listed on the stock market since June 30, 2021. Its lead product, Renal Autologous Cell Therapy (REACT), uses a patient's own kidney cells to preserve kidney function in chronic kidney disease patients. REACT is currently in global Phase 3 trials and multiple Phase 2 trials for diabetic kidney disease. Prokidney is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prokidney stock

Stock-Based Compensation (SBC) of Prokidney is 25.34 M USD in 2025.

Stock-Based Compensation (SBC) of Prokidney changed from 29.37 M USD to 25.34 M USD, representing a -13.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Prokidney since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Prokidney historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Prokidney

All Key Metrics — Prokidney